a NHMRC Clinical Trials Centre , The University of Sydney , Camperdown , Australia.
b Medical Oncology, The Queen Elizabeth Hospital , Woodville Australia.
Expert Rev Anticancer Ther. 2018 Apr;18(4):339-349. doi: 10.1080/14737140.2018.1444481. Epub 2018 Mar 1.
Oxaliplatin-based adjuvant chemotherapy has been the standard of care for resected early colon cancer for over a decade. Recent results from the IDEA meta-analysis attempt to address the question of whether 3 or 6 months of adjuvant chemotherapy is preferable in Stage III colon cancer. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of adjuvant therapy for resected early colon cancers. This article reviews the current evidence for adjuvant treatment of Stage II and III colon cancer, as well as up-to-date data regarding optimal duration of therapy. This article reviews the evidence for lifestyle modifications in the management of early colorectal cancer and other future directions for research in early colon cancer. Expert commentary: In recent years, there have been no advances in the development of novel agents for adjuvant therapy in colorectal cancer. Although the IDEA meta-analysis was negative for its primary non-inferiority endpoint, the detailed results provide valuable information that allows personalisation of treatment regimen and duration.
奥沙利铂为基础的辅助化疗已经成为十年来治疗切除的早期结肠癌的标准治疗方法。最近的 IDEA 荟萃分析结果试图解决在 III 期结肠癌中，辅助化疗 3 个月还是 6 个月更优的问题。
对早期结肠癌辅助治疗的相关文献进行了回顾，并对最近的会议报告进行了综述。本文综述了 II 期和 III 期结肠癌辅助治疗的最新证据，以及关于最佳治疗持续时间的最新数据。本文还回顾了生活方式改变在早期结直肠癌治疗中的应用证据，以及早期结肠癌未来的研究方向。
近年来，在结直肠癌的辅助治疗中，没有新药物的进展。尽管 IDEA 荟萃分析在其主要的非劣效性终点上为阴性，但详细的结果提供了有价值的信息，使治疗方案和持续时间的个体化成为可能。
